Smokeless tobacco has been evolving over the past 55 years and now, with various forms of e-cigarettes and additives available, this once ‘safer’ recreational activity is showing implications on brain, lung, and cardiovascular function.
Aducanumab (Aduhelm), a new drug designed to treat Alzheimer's disease was approved by the FDA on June 7, 2021. RGA's Dr. Dave Rengachary discusses what this means for insurance, as well as the controversies around it.
Hypertension, or high blood pressure, is a common medical problem. It can be caused by a number of other medical conditions such as chronic kidney disease, thyroid disorders and other hormonal upsets, and a rare adrenal gland tumor called pheochromocytoma.
RGA’s consultant oncologist, Dr. Radi Counsell, discusses the ways liquid biopsies will change the face of cancer care, from screening and diagnosis to treatment monitoring and surveillance of survivors. Dr. Counsell also examines underwriting and claims adjudication implications of this emerging technology.
Rapid advances in medical science’s understanding of the human genome have led to the recent development of novel gene-based therapeutic strategies. In ReFlections, RGA's Dr. Dan Zimmerman defines gene and cell therapies and provides insights into these rapidly developing and impactful technologies.
The global burden of gestational diabetes mellitus (GDM) is on the rise alongside increases in obesity and changing lifestyles. In ReFlections, RGA's Dr. Reema Nathwani Jani explores the history, complications, management, and long-term outcomes of GDM on maternal morbidity and fetal mortality, as well as links with diabetes, CVD, and cancer risks.
Quest continues to monitor COVID-19 and contribute to the scientific community’s understanding of this novel disease.
While clinicians have a better understanding of COVID‑19 disease, science is still struggling to make sense of its long-lasting symptoms, known as Long COVID, and what “long haulers” have in common.
When assessing glycemic control in the majority of our applicants, hemoglobin A1c is the gold standard for assessing glucose control over an intermediate period of time.
A series of clinical trials examining biomarkers to reduce cancer deaths by around 20% could revolutionize cancer care. What does this mean for insurers?
 |
 |
 |
 |
 |
 |